Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients

Detalhes bibliográficos
Autor(a) principal: Costa-Carvalho,B.T.
Data de Publicação: 2006
Outros Autores: Martinez,R.M.A., Dias,A.T.N., Kubo,C.A., Barros-Nunes,P., Leiva,L., Solé,D., Carneiro-Sampaio,M.M.S., Naspitz,C.K., Sorensen,R.U.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Medical and Biological Research
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001200010
Resumo: The majority of children with Down syndrome (DS) tend to have frequent bacterial infections including recurrent respiratory infections. Our objective was to evaluate the production of antibodies to pneumococcal polysaccharide antigens after active immunization in DS subjects. IgG antibodies to pneumococcal serotypes (1, 3, 6B, 9V, and 14) were measured before and 6 weeks after immunization with a 23-valent pneumococcal vaccine (Pneumo23®, Pasteur-Merrieux) in 6- to 13-year-old DS children (N = 17) and in aged-matched normal controls (N = 30). An adequate response was defined as a 4-fold increase over baseline or a post-immunization level of specific pneumococcal serotype antibody > or = 1.3 µg/mL. After immunization, all DS children had an increase in post-immunization levels against all serotypes analyzed. A 4-fold or more increase was observed in all DS children concerning serotypes 1 and 14, in 90% of subjects for serotypes 3 and 9V, and in 65% for serotype 6B. Regarding this increase, 8 of the 17 DS children had an adequate response to all serotypes analyzed, 8/17 patients to 4 serotypes and 1/17 to 3 serotypes. However, when we compared post-immunization levels between DS children and controls, we observed lower levels in the former group (P < 0.05) for all serotypes except serotype 3. We conclude that pneumococcal polysaccharide immunization could be beneficial for these DS children.
id ABDC-1_d12236af4421b00e10fa951b1b2beb76
oai_identifier_str oai:scielo:S0100-879X2006001200010
network_acronym_str ABDC-1
network_name_str Brazilian Journal of Medical and Biological Research
repository_id_str
spelling Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patientsDown syndromeImmunoglobulinIgG subclassPolysaccharide vaccineStreptococcus pneumoniaePneumococcal antibodiesThe majority of children with Down syndrome (DS) tend to have frequent bacterial infections including recurrent respiratory infections. Our objective was to evaluate the production of antibodies to pneumococcal polysaccharide antigens after active immunization in DS subjects. IgG antibodies to pneumococcal serotypes (1, 3, 6B, 9V, and 14) were measured before and 6 weeks after immunization with a 23-valent pneumococcal vaccine (Pneumo23®, Pasteur-Merrieux) in 6- to 13-year-old DS children (N = 17) and in aged-matched normal controls (N = 30). An adequate response was defined as a 4-fold increase over baseline or a post-immunization level of specific pneumococcal serotype antibody > or = 1.3 µg/mL. After immunization, all DS children had an increase in post-immunization levels against all serotypes analyzed. A 4-fold or more increase was observed in all DS children concerning serotypes 1 and 14, in 90% of subjects for serotypes 3 and 9V, and in 65% for serotype 6B. Regarding this increase, 8 of the 17 DS children had an adequate response to all serotypes analyzed, 8/17 patients to 4 serotypes and 1/17 to 3 serotypes. However, when we compared post-immunization levels between DS children and controls, we observed lower levels in the former group (P < 0.05) for all serotypes except serotype 3. We conclude that pneumococcal polysaccharide immunization could be beneficial for these DS children.Associação Brasileira de Divulgação Científica2006-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001200010Brazilian Journal of Medical and Biological Research v.39 n.12 2006reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/S0100-879X2006005000047info:eu-repo/semantics/openAccessCosta-Carvalho,B.T.Martinez,R.M.A.Dias,A.T.N.Kubo,C.A.Barros-Nunes,P.Leiva,L.Solé,D.Carneiro-Sampaio,M.M.S.Naspitz,C.K.Sorensen,R.U.eng2008-02-12T00:00:00Zoai:scielo:S0100-879X2006001200010Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:2008-02-12T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false
dc.title.none.fl_str_mv Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients
title Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients
spellingShingle Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients
Costa-Carvalho,B.T.
Down syndrome
Immunoglobulin
IgG subclass
Polysaccharide vaccine
Streptococcus pneumoniae
Pneumococcal antibodies
title_short Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients
title_full Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients
title_fullStr Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients
title_full_unstemmed Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients
title_sort Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients
author Costa-Carvalho,B.T.
author_facet Costa-Carvalho,B.T.
Martinez,R.M.A.
Dias,A.T.N.
Kubo,C.A.
Barros-Nunes,P.
Leiva,L.
Solé,D.
Carneiro-Sampaio,M.M.S.
Naspitz,C.K.
Sorensen,R.U.
author_role author
author2 Martinez,R.M.A.
Dias,A.T.N.
Kubo,C.A.
Barros-Nunes,P.
Leiva,L.
Solé,D.
Carneiro-Sampaio,M.M.S.
Naspitz,C.K.
Sorensen,R.U.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Costa-Carvalho,B.T.
Martinez,R.M.A.
Dias,A.T.N.
Kubo,C.A.
Barros-Nunes,P.
Leiva,L.
Solé,D.
Carneiro-Sampaio,M.M.S.
Naspitz,C.K.
Sorensen,R.U.
dc.subject.por.fl_str_mv Down syndrome
Immunoglobulin
IgG subclass
Polysaccharide vaccine
Streptococcus pneumoniae
Pneumococcal antibodies
topic Down syndrome
Immunoglobulin
IgG subclass
Polysaccharide vaccine
Streptococcus pneumoniae
Pneumococcal antibodies
description The majority of children with Down syndrome (DS) tend to have frequent bacterial infections including recurrent respiratory infections. Our objective was to evaluate the production of antibodies to pneumococcal polysaccharide antigens after active immunization in DS subjects. IgG antibodies to pneumococcal serotypes (1, 3, 6B, 9V, and 14) were measured before and 6 weeks after immunization with a 23-valent pneumococcal vaccine (Pneumo23®, Pasteur-Merrieux) in 6- to 13-year-old DS children (N = 17) and in aged-matched normal controls (N = 30). An adequate response was defined as a 4-fold increase over baseline or a post-immunization level of specific pneumococcal serotype antibody > or = 1.3 µg/mL. After immunization, all DS children had an increase in post-immunization levels against all serotypes analyzed. A 4-fold or more increase was observed in all DS children concerning serotypes 1 and 14, in 90% of subjects for serotypes 3 and 9V, and in 65% for serotype 6B. Regarding this increase, 8 of the 17 DS children had an adequate response to all serotypes analyzed, 8/17 patients to 4 serotypes and 1/17 to 3 serotypes. However, when we compared post-immunization levels between DS children and controls, we observed lower levels in the former group (P < 0.05) for all serotypes except serotype 3. We conclude that pneumococcal polysaccharide immunization could be beneficial for these DS children.
publishDate 2006
dc.date.none.fl_str_mv 2006-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001200010
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2006001200010
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0100-879X2006005000047
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
dc.source.none.fl_str_mv Brazilian Journal of Medical and Biological Research v.39 n.12 2006
reponame:Brazilian Journal of Medical and Biological Research
instname:Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
instname_str Associação Brasileira de Divulgação Científica (ABDC)
instacron_str ABDC
institution ABDC
reponame_str Brazilian Journal of Medical and Biological Research
collection Brazilian Journal of Medical and Biological Research
repository.name.fl_str_mv Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)
repository.mail.fl_str_mv bjournal@terra.com.br||bjournal@terra.com.br
_version_ 1754302935069622272